Evidence map›Paper›PMID 37097631›Full record

ArticleJAMA network open2023

Measurement of Dimensions of Self-awareness of Memory Function and Their Association With Clinical Progression in Cognitively Normal Older Adults.

Kayden J Mimmack, Geoffroy P Gagliardi, Gad A Marshall, Patrizia Vannini, Alzheimer’s Disease Neuroimaging Initiative

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Subjective cognitive decline: Memory complaints, cognitive awareness, and metacognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Kayden J MimmackDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
Geoffroy P GagliardiDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Gad A MarshallDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
Patrizia VanniniDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.
Alzheimer’s Disease Neuroimaging Initiative
Alzheimer’s Disease Neuroimaging Initiative · USBrigham and Women's Hospital · USHarvard University · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
Novel automated performance-based ADL outcomes for early AD clinical trialsR01AG053184 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI MARSHALL, GAD ASHER · 2018 to 2023
$4.5M
Decoding neural systems underlying anosognosia for memory loss in aging and Alzheimer's diseaseR01AG061083 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI VANNINI, PATRIZIA · 2019 to 2023
$4.3M
NCATS NIH HHS UL1 TR002541NIA NIH HHS R01 AG053184NIA NIH HHS R01 AG061083NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Importance: The ability to separately explore 2 dimensions of self-awareness of memory function-increased and decreased awareness-in cognitively normal older adults provides an important opportunity to understand subtle changes in either direction in relation to risk of Alzheimer disease. Objective: To investigate the association of a novel measure for self-awareness of memory function with future clinical progression in individuals who were cognitively normal at baseline. Design, Setting, and Participants: This cohort study used data from the Alzheimer's Disease Neuroimaging Initiative, a multicenter study. Participants were older adults who were cognitively normal (ie, Clinical Dementia Rating [CDR] global score of 0) at baseline and had at least 2 years of follow-up. Data were collected from June 2010 to December 2021 and pulled from the University of Southern California Laboratory of Neuro Imaging database on January 18, 2022. Clinical progression was defined as the first instance of 2 consecutive follow-up CDR scale global scores of 0.5 or greater. Main Outcomes and Measures: A traditional awareness score was measured by calculating the mean discrepancy between the participant and their study partner's scores on the Everyday Cognition questionnaire. An unawareness or heightened awareness subscore was generated by capping item-level positive or negative differences at zero before averaging. The main outcome-risk of future clinical progression-was analyzed for each baseline awareness measure using Cox regression analysis. Longitudinal trajectories of each measure were additionally compared using linear mixed-effects models. Results: The 436-person sample included 232 (53.2%) female participants, with a mean (SD) age of 74.5 (6.7) years; 25 participants (5.7%) were Black, 14 (3.2%) Hispanic, and 398 (91.3%) White; and 91 participants (20.9%) clinically progressed over their period of observation. Survival analyses showed that a 1-point improvement on the unawareness subscore was associated with an 84% reduction in progression hazard (hazard ratio, 0.16 [95% CI, 0.07-0.35]; P < .001), or equivalently, a 1-point decrease was associated with a 540% increase in progression hazard (95% CI, 183% to 1347%), with no significant results for the heightened awareness or traditional scores. Conclusions and Relevance: In this cohort study of 436 cognitively normal older adults, unawareness, rather than heightened awareness, of memory decline was strongly associated with future clinical progression, providing further support that discordant self- and informant-reported cognitive decline may provide important information to practitioners.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedCohort StudiesDisease ProgressionFemaleHumansMaleNeuropsychological Tests

Identifiers

PMID37097631
PMCPMC10130951
OpenAlexW4366983676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.